Revalesio Unveils Promising Results from Phase 2 RESCUE Trial at SVIN 2025

Revalesio Presents Findings from Phase 2 RESCUE Trial at SVIN 2025

In an exciting development for neurological treatment, Revalesio, a clinical-stage biopharmaceutical company, has announced that it will present findings from a post-hoc analysis of its Phase 2 RESCUE trial at the Society of Vascular and Interventional Neurology (SVIN) Annual Meeting, held from November 19 to 22, 2025, in Orlando, Florida. The research highlights the effectiveness of RNS60, an investigational therapy that could potentially reduce hospital stays for stroke patients.

The RESCUE trial aimed to explore solutions for patients suffering from acute ischemic strokes, a condition that occurs when blood flow to the brain is obstructed, leading to severe neurological damage. This groundbreaking study assessed the impact of RNS60, an oxygen-supersaturated saline therapy designed to protect brain tissue by enhancing mitochondrial activity and reducing inflammation.

Dr. Supurna Ghosh, the Vice President of Translational Medicine at Revalesio, is scheduled to present the findings on November 21, focusing on how RNS60 affects hospital discharge rates and overall patient recovery. The presentation, titled "Post Hoc Analysis of RESCUE Trial Shows Shortened Hospital Stay and Higher Rate of Discharge to Home in Participants Treated with RNS60," will serve as a platform to disseminate essential insights from this pivotal research.

In the Phase 2 RESCUE trial, results indicated that RNS60 users experienced a remarkable 50% decrease in brain tissue loss compared to those not receiving the treatment. Additionally, it seemed to facilitate improved functional recovery among those treated within 12 or 24 hours after the onset of a stroke. These outcomes not only signify advancements in neuroprotective treatment approaches but also indicate potential economic benefits arising from reduced hospital stays.

Dr. Ghosh emphasized, "Our latest analysis underscores RNS60's potential not just to preserve brain tissue, but also to help patients regain independence and recover more quickly." Such statements reflect Revalesio's commitment to revolutionizing stroke care through cytoprotection—a concept that focuses on enabling and preserving normal cellular function during injury or trauma.

Looking ahead, Revalesio is preparing to embark on a Phase 3 trial for RNS60, with the primary objective of validating its effectiveness in enhancing recovery outcomes for patients undergoing endovascular thrombectomy, a surgical procedure designed to remove blood clots from the brain.

RNS60 is not merely confined to stroke treatment but is being explored for various neurological conditions, including Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease. The FDA has granted Fast Track designation for RNS60, signifying its potential to address an urgent medical need in the realm of acute ischemic stroke treatment.

The implications of these findings could reshape the landscape of stroke care, focusing not only on immediate treatment but also on the long-term recovery trajectory of patients. The upcoming oral presentation at the SVIN Annual Meeting aims to amplify awareness and discussion surrounding the vital role of cytoprotection in modern medical practices.

For additional information about Revalesio and its clinical programs, please visit their official website and engage with their content on social media platforms.